rivaroxaban ratiopharm 20 mg tabletti, kalvopäällysteinen
ratiopharm gmbh - rivaroxaban - tabletti, kalvopäällysteinen - 20 mg - rivaroksabaani
rivaroxaban ratiopharm 15 mg + 20 mg tabletti, kalvopäällysteinen
ratiopharm gmbh - rivaroxaban - tabletti, kalvopäällysteinen - 15 mg + 20 mg - rivaroksabaani
rivaroxaban viatris (previously rivaroxaban mylan)
mylan ireland limited - rivaroksabaani - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitromboottiset aineet - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers. rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
rivaroxaban avansor 20 mg tabletti, kalvopäällysteinen
avansor pharma oy - rivaroxaban - tabletti, kalvopäällysteinen - 20 mg - rivaroksabaani
rivaroxaban avansor 15 mg tabletti, kalvopäällysteinen
avansor pharma oy - rivaroxaban - tabletti, kalvopäällysteinen - 15 mg - rivaroksabaani
rivaroxaban avansor 10 mg tabletti, kalvopäällysteinen
avansor pharma oy - rivaroxaban - tabletti, kalvopäällysteinen - 10 mg - rivaroksabaani
misbadi 150 mg kapseli, kova
towa pharmaceutical europe s.l. - dabigatran etexilate mesilate - kapseli, kova - 150 mg - dabigatraanieteksilaatti
misbadi 110 mg kapseli, kova
towa pharmaceutical europe s.l. - dabigatran etexilate mesilate - kapseli, kova - 110 mg - dabigatraanieteksilaatti
misbadi 75 mg kapseli, kova
towa pharmaceutical europe s.l. - dabigatran etexilate mesilate - kapseli, kova - 75 mg - dabigatraanieteksilaatti
apixaban stada 5 mg tabletti, kalvopäällysteinen
stada arzneimittel ag - apixaban - tabletti, kalvopäällysteinen - 5 mg - apiksabaani